Companies / GSS

GENETIC SIGNATURES LIMITED

ASX:GSSPharmaceuticals, Biotechnology & Life Sciences
227.1M shares on issueASX (delayed) · as of 28 July 2026$0.060price · delayed$13.6Mmarket cap · indicative
A
Dilution grade

Runway 4–8 quarters

Cash runway6.0 quarters of funding
Share-count growth (24m)0.3%
Raise cadence (24m)0 cash raises
Options & rights overhang3.9% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

GENETIC SIGNATURES LIMITED's ordinary share count was 227M as of December 2024, a 0.3% change since July 2024. The company did not raise capital in the most recent 24-month window. Options and rights on issue could convert into 9M new shares, equal to 3.9% of the current share count, with 0% in the money and the nearest expiry in November 2035. At the June 2026 quarter the company reported A$21.0M in available cash, covering 6.0 quarters at its recent spending rate. No proposed securities issues (Appendix 3B) are currently pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
3.9%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
6.0 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 227.1M per ASX (delayed) (28 July 2026).
227.09M227.11M227.12MDec 24Sept 25July 26

Cash runway

6.0 qtrs
More than four quarters of funding at the recent spend rate.
$21.0M available cash at quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
29 Mar 20263H · cancellationGSS : ORDINARY FULLY PAID227.1MAppendix 3H
10 Feb 20263H · cancellationGSS : ORDINARY FULLY PAID227.1MAppendix 3H
24 Nov 20253G · unquotedGSS : ORDINARY FULLY PAID227.1MAppendix 3G
21 Nov 20253H · cancellationGSS : ORDINARY FULLY PAID227.1MAppendix 3H
6 Nov 20253G · unquotedGSS : ORDINARY FULLY PAID227.1MAppendix 3G
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

3.9%
Total overhang · of current shares
0.0%
In the money · at current price
8.8M
Potential new shares
Nov 2035
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
24 Nov 2025Dr Jenny HarryOther250k——3Y notice
24 Nov 2025Anne LockwoodOther250k——3Y notice
6 Dec 2024Dr Neil GunnOther—500k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

23 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
2 July 2026Becoming a substantial holder from BDX
2 July 2026$PGSS responds to the BCAL Diagnostics Announcement
1 July 2026Ceasing to be a substantial holder
18 June 2026Change of Company Secretary
18 June 2026Change in substantial holding
16 June 2026Change in substantial holding
9 June 2026Investor Presentation
8 June 2026Investor Webinar Notification
7 May 2026Final Director's Interest Notice
7 May 2026Board Reorganisation
29 Apr 2026Change in substantial holding
28 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
22 Apr 2026Change in substantial holding
17 Apr 2026Change in substantial holding
17 Apr 2026Change in substantial holding
15 Apr 2026$PDanish Supply Agreement - Additional Information
15 Apr 2026$PPause in Trading
14 Apr 2026$PGenetic Signatures Signs Danish Supply Agreement
29 Mar 2026$PGenetic Signatures Organisational Restructure

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.